Tevimbra - opinion on variation to marketing authorisation

Opinion

EMA has issued an opinion on a change to this medicine's authorisation.

tislelizumab

Opinion

On 17 October 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Tevimbra. The marketing authorisation holder for this medicinal product is Beigene Ireland Limited.

The CHMP adopted a new indication to extend the use of Tevimbra to patients with gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, as follows:

Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Tevimbra, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adult patients with HER-2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumours express PD‑L1 with a tumour area positivity (TAP) score ≥ 5% (see section 5.1).

For information, the full indications for Tevimbra will be as follows¹:

Non-small cell lung cancer (NSCLC)
Tevimbra in combination with pemetrexed and platinum‑containing chemotherapy is indicated for the first-line treatment of adult patients with non-squamous NSCLC whose tumours have PD-L1 expression on ≥50% of tumour cells with no EGFR or ALK positive mutations and who have:

• locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or
• metastatic NSCLC.

Tevimbra in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of adult patients with squamous NSCLC who have:

• locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or
• metastatic NSCLC.

Tevimbra as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior platinum-based therapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab.

Gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Tevimbra, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adult patients with HER-2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumours express PD‑L1 with a tumour area positivity (TAP) score ≥ 5% (see section 5.1).

Oesophageal squamous cell carcinoma (OSCC)

Tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic OSCC after prior platinum-based chemotherapy.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR) and made available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

---

¹ New text in bold

CHMP post-authorisation summary of positive opinion for Tevimbra (II-06)

AdoptedReference Number: EMA/CHMP/435989/2024

Key facts

• Name of medicine:
  Tevimbra
• EMA product number:
  EMEA/H/C/005919
• Active substance:
  Tislelizumab
• International non-proprietary name (INN) or common name:
  tislelizumab
• Therapeutic area (MeSH):
  Esophageal Squamous Cell Carcinoma
• Anatomical therapeutical chemical (ATC) code:
  L01FF09
• Additional monitoring:

  This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

• Marketing authorisation holder:
  BeiGene Ireland Ltd
• Date of opinion:
  17/10/2024
• Status:
  Positive